REVIEW

Long noncoding RNAs are a promising therapeutic target in various diseases

About authors

1 Laboratory of Functional Genomics,
Research Centre of Medical Genetics, Moscow, Russia

2 Laboratory of Medical Genetic Technologies, Department of Basic Research of MDRI,
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

3 Genomic Functional Analysis Laboratory,
Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russia

Correspondence should be addressed: Alexandra Filatova
ul. Moskvorechie, d. 1, Moscow, Russia, 115478; ur.xednay@ccaam

About paper

Contribution of the authors to this work: Filatova AYu — planning, literature analysis, drafting of a manuscript; Sparber PA — literature analysis, drafting of a manuscript; Krivosheeva IA — literature analysis, drafting of a manuscript; Skoblov MYu — drafting of a manuscript. All authors participated in editing of the manuscript.

Received: 2017-06-25 Accepted: 2017-06-28 Published online: 2017-07-18
|
The figure shows some of the gene therapy approaches targeting long noncoding RNA (lncRNA). (A) Transcription repression by CRISPRi. (B) RNA interference. (C) Antisense oligonucleotides (ASOs) activate RNAse H — dependent degradation of the RNA target by forming an RNA-DNA duplex. (D) ASOs block lncRNA binding to the repressive PRC2 complex